| Completed |
: Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
: - Brenner Tumor
- Fallopian Tube Cancer
-
- Drug: belinostat Given IV
|
| Completed |
: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
: - Brenner Tumor
- Fallopian Tube Cancer
-
- Biological: sargramostim Given
|
| Completed |
: Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
: - Brenner Tumor
- Fallopian Tube Cancer
-
- Drug: carboplatin Given intrap
|
| Completed |
: Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
: - Brenner Tumor
- Fallopian Tube Cancer
-
- Procedure: adjuvant therapy
- Drug: paclitax
|
| Completed |
: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Carcinoma
- Malignant Ovarian Mixed Epithelial Tumor
-
- Biological: Urokinase-Derived Peptide A6
|
| Recruiting |
: MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer
: - Malignant Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcino
: 2014-02-19
: - Other: Laboratory Biomarker Analysis
|
| Withdrawn |
: Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
: - Fatigue
- Malignant Ovarian Mixed Epithelial Tumor
- Neuropath
: 2011-12-14
: - Dietary Supplement: Acetyl-L-Carnitine Hydrochloride
|
| Active, not recruiting |
: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
: 2009-04-24
: - Drug: Elesclomol Sodium Given
|
| Recruiting |
: Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
: - Clear Cell Adenocarcinoma
- Fallopian Tube Clear Cell Adenocarcinoma
-
- Biological: Bevacizumab Given
|
| Completed |
: Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
: - Chemotherapeutic Agent Toxicity
- Endometrial Adenocarcinoma
: 2008-12-20
: - Drug: Paclitaxel Given IV or i
|
